会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • Peptide stellate carrier devices for stellate cells
    • 用于星状细胞的肽星形载体装置
    • US20050227916A1
    • 2005-10-13
    • US11012056
    • 2004-12-15
    • Klaas PoelstraEleonora BeljaarsDirk MeijerDetlef Schuppan
    • Klaas PoelstraEleonora BeljaarsDirk MeijerDetlef Schuppan
    • G01N33/566A61K9/00A61K38/12A61K47/42A61K47/48A61K51/08A61P1/00A61P7/00A61P9/10A61P11/00A61P13/00A61P19/02A61P29/00A61P43/00C07K14/71C07K14/715C07K14/765C07K19/00C12Q1/02G01N33/15
    • A61K38/12A61K47/549A61K47/62A61K47/643A61K51/0491A61K51/081
    • A compound includes a carrier molecule wherein the carrier molecule is linked to a further molecule, wherein the further molecule is at least one cyclic peptide in which the cyclic peptide portion thereof contains at least one sequence encoding a cell receptor recognizing peptide (RRP) and with the proviso that the compound is not a naturally occurring receptor agonist or antagonist. Preferably, the RRP is a receptor specific for Hepatic Stellate Cells (HSC) or a receptor that is up-regulated on HSC during disease. The RFP may be chosen from among a PDGF receptor, a collagen type VI receptor, cytokine receptor(s) such as TGBβ, INFα and interleukinβ. The cyclic portion of the peptide can contain at least one amino acid sequence RGD or KPT. The compounds can be used as an active targeting ingredient for manufacturing a pharmaceutical composition for therapy, prophylaxis or diagnosis of a disease chosen from fibrotic disease, sclerotic disease, and chronic or acute inflammatory processes including glomeruloscherosis, interstitial fibrosis, lung fibrosis, atherosclerosis, rheumatoid arthritis, Crohns disease, colitis ulcerosa, glomerulonephritis and sepsis, and particularly for targeting HSC. Pharmaceutical compositions contain the above-compound(s).
    • 化合物包括载体分子,其中载体分子与另一分子连接,其中另外的分子是至少一个环肽,其中环肽部分含有至少一个编码细胞受体识别肽(RRP)的序列, 条件是该化合物不是天然存在的受体激动剂或拮抗剂。 优选地,RRP是对肝星状细胞(HSC)特异的受体或在疾病期间在HSC上上调的受体。 RFP可以选自PDGF受体,胶原型VI受体,细胞因子受体(例如TGBbeta,INFalpha和白介素β)。 肽的环状部分可以含有至少一个氨基酸序列RGD或KPT。 该化合物可用作制备用于治疗,预防或诊断选自纤维化疾病,硬化性疾病和慢性或急性炎症过程(包括肾小球硬化,间质性纤维化,肺纤维化,动脉粥样硬化,类风湿病)的药物组合物的活性靶向成分 关节炎,克罗恩病,溃疡性结肠炎,肾小球性肾炎和败血症,特别是靶向HSC。 药物组合物含有上述化合物。
    • 2. 发明申请
    • Peptide-based carrier devices for stellate cells
    • 用于星状细胞的基于肽的载体装置
    • US20080267877A1
    • 2008-10-30
    • US12076802
    • 2008-03-24
    • Klaas PoelstraEleonora BeljaarsDirk Klaas Fokke MeijerDetlef Bruno Igor Schuppan
    • Klaas PoelstraEleonora BeljaarsDirk Klaas Fokke MeijerDetlef Bruno Igor Schuppan
    • A61K49/00C12Q1/02
    • A61K38/12A61K47/549A61K47/62A61K47/643A61K51/0491A61K51/081
    • A compound includes a carrier molecule wherein the carrier molecule is linked to a further molecule, wherein the further molecule is at least one cyclic peptide in which the cyclic peptide portion thereof contains at least one sequence encoding a cell receptor recognizing peptide (RRP) and with the proviso that the compound is not a naturally occurring receptor agonist or antagonist. Preferably, the RRP is a receptor specific for Hepatic Stellate Cells (HSC) or a receptor that is up-regulated on HSC during disease. The RFP may be chosen from among a PDGF receptor, a collagen type VI receptor, cytokine receptor(s) such as TGBβ, INFα and interleukinβ. The cyclic portion of the peptide can contain at least one amino acid sequence RGD or KPT. The compounds can be used as an active targeting ingredient for manufacturing a pharmaceutical composition for therapy, prophylaxis or diagnosis of a disease chosen from fibrotic disease, sclerotic disease, and chronic or acute inflammatory processes including glomeruloscherosis, interstitial fibrosis, lung fibrosis, atherosclerosis, rheumatoid arthritis, Crohns disease, colitis ulcerosa, glomerulonephritis and sepsis, and particularly for targeting HSC. Pharmaceutical compositions contain the above-compound(s).
    • 化合物包括载体分子,其中载体分子与另一分子连接,其中另外的分子是至少一个环肽,其中环肽部分含有至少一个编码细胞受体识别肽(RRP)的序列, 条件是该化合物不是天然存在的受体激动剂或拮抗剂。 优选地,RRP是对肝星状细胞(HSC)特异的受体或在疾病期间在HSC上上调的受体。 RFP可以选自PDGF受体,胶原型VI受体,细胞因子受体(例如TGBbeta,INFalpha和白介素β)。 肽的环状部分可以含有至少一个氨基酸序列RGD或KPT。 该化合物可用作制备用于治疗,预防或诊断选自纤维化疾病,硬化性疾病和慢性或急性炎症过程(包括肾小球硬化,间质性纤维化,肺纤维化,动脉粥样硬化,类风湿病)的药物组合物的活性靶向成分 关节炎,克罗恩病,溃疡性结肠炎,肾小球性肾炎和败血症,特别是靶向HSC。 药物组合物含有上述化合物。
    • 5. 发明授权
    • Peptide-based carrier devices for stellate cells
    • 用于星状细胞的基于肽的载体装置
    • US06844319B1
    • 2005-01-18
    • US09806837
    • 1998-10-08
    • Klaas PoelstraEleonora BeljaarsDirk Klaas Fokke MeijerDetlef Bruno Igor Schuppan
    • Klaas PoelstraEleonora BeljaarsDirk Klaas Fokke MeijerDetlef Bruno Igor Schuppan
    • G01N33/566A61K9/00A61K38/12A61K47/42A61K47/48A61K51/08A61P1/00A61P7/00A61P9/10A61P11/00A61P13/00A61P19/02A61P29/00A61P43/00C07K14/71C07K14/715C07K14/765C07K19/00C12Q1/02G01N33/15A61K38/00C07K11/02
    • A61K38/12A61K47/549A61K47/62A61K47/643A61K51/0491A61K51/081
    • The present invention relates to a compound comprising a carrier molecule, said carrier molecule being linked to a further molecule, said further molecule being at least one cyclic peptide, said cyclic peptide comprising in the cyclic peptide portion thereof at least one sequence encoding a cell receptor recognising peptide (RRP) and with the proviso that the compound is not a naturally occuring receptor agonist or antagonist. Preferably, the RRP is of a receptor specific for Hepatic Stellate Cells (HSC) or a receptor that is upregulated on HSC during disease. In particular, the RRP may be of a receptor selected from the group of PDGF receptor, collagen type VI receptor, cytokine receptor(s) such as TGFβ, IFNα and interleukin 1β. Preferably, the cyclic portion of the cyclic peptide comprises at least the amino acid sequence RGD or KPT. The compounds can be used as an active targeting ingredient for manufacturing a pharmaceutical composition for therapy, prophylaxis or diagnosis of a disease selected from the group consisting of fibrotic disease, sclerotic disease and chronic or acute inflammatory processes such as glomerulosclerosis, interstitial fibrosis, lung fibrosis, atherosclerosis, rheumatoid arthritis, Crohns disease, colitis ulcerosa, glomerulonephritis and sepsis, in particular for targeting HSC. The invention also relates to pharmaceutial compositions comprising the above compound(s).
    • 本发明涉及包含载体分子的化合物,所述载体分子与另一个分子连接,所述另外的分子是至少一个环肽,所述环肽在其环肽部分中包含至少一个编码细胞受体的序列 识别肽(RRP),条件是该化合物不是天然存在的受体激动剂或拮抗剂。 优选地,RRP是肝星状细胞(HSC)特异的受体或在疾病期间在HSC上被上调的受体。 特别地,RRP可以是选自PDGF受体,胶原型VI受体,细胞因子受体(例如TGFbeta,IFNα和白细胞介素1beta)的受体。 优选地,环肽的环状部分至少包含氨基酸序列RGD或KPT。 该化合物可用作制备用于治疗,预防或诊断选自纤维化疾病,硬化性疾病和慢性或急性炎症过程如肾小球硬化,间质纤维化,肺纤维化的疾病的药物组合物的活性靶向成分 ,动脉粥样硬化,类风湿性关节炎,克罗恩病,溃疡性结肠炎,肾小球性肾炎和败血症,特别是靶向HSC。 本发明还涉及包含上述化合物的药物组合物。
    • 6. 发明授权
    • Method for targeting cells involved in sclerotic and/or fibrotic diseases
    • 用于靶向涉及硬化和/或纤维化疾病的细胞的方法
    • US07348313B2
    • 2008-03-25
    • US11012056
    • 2004-12-15
    • Klaus PoelstraEleonora BeljaarsDrik Klaus Fokke MeijerDetlef Bruno Igor Schuppan
    • Klaus PoelstraEleonora BeljaarsDrik Klaus Fokke MeijerDetlef Bruno Igor Schuppan
    • A61K31/7004
    • A61K38/12A61K47/549A61K47/62A61K47/643A61K51/0491A61K51/081
    • A compound includes a carrier molecule wherein the carrier molecule is linked to a further molecule, wherein the further molecule is at least one cyclic peptide in which the cyclic peptide portion thereof contains at least one sequence encoding a cell receptor recognizing peptide (RRP) and with the proviso that the compound is not a naturally occurring receptor agonist or antagonist. Preferably, the RRP is a receptor specific for Hepatic Stellate Cells (HSC) or a receptor that is up-regulated on HSC during disease. The RFP may be chosen from among a PDGF receptor, a collagen type VI receptor, cytokine receptor(s) such as TGBβ, INFα and interleukinβ. The cyclic portion of the peptide can contain at least one amino acid sequence RGD or KPT. The compounds can be used as an active targeting ingredient for manufacturing a pharmaceutical composition for therapy, prophylaxis or diagnosis of a disease chosen from fibrotic disease, sclerotic disease, and chronic or acute inflammatory processes including glomeruloscherosis, interstitial fibrosis, lung fibrosis, atherosclerosis, rheumatoid arthritis, Crohns disease, colitis ulcerosa, glomerulonephritis and sepsis, and particularly for targeting HSC. Pharmaceutical compositions contain the above-compound(s).
    • 化合物包括载体分子,其中载体分子与另一分子连接,其中另外的分子是至少一个环肽,其中环肽部分含有至少一个编码细胞受体识别肽(RRP)的序列, 条件是该化合物不是天然存在的受体激动剂或拮抗剂。 优选地,RRP是对肝星状细胞(HSC)特异的受体或在疾病期间在HSC上上调的受体。 RFP可以选自PDGF受体,胶原型VI受体,细胞因子受体(例如TGBbeta,INFalpha和白介素β)。 肽的环状部分可以含有至少一个氨基酸序列RGD或KPT。 该化合物可用作制备用于治疗,预防或诊断选自纤维化疾病,硬化性疾病和慢性或急性炎症过程(包括肾小球硬化,间质性纤维化,肺纤维化,动脉粥样硬化,类风湿病)的药物组合物的活性靶向成分 关节炎,克罗恩病,溃疡性结肠炎,肾小球性肾炎和败血症,特别是靶向HSC。 药物组合物含有上述化合物。